We also conduct 360 assessments to help associates assess their individual development and progression based on feedback from key stakeholders. Participants engage in a 360 assessment feedback process and are assigned an executive mentor, which are used to identify opportunities to develop key aspects of their leadership and share their personal leadership journey with executives. International standards cover areas of Quality, Environmental, Health and Safety, Automotive, Medical Device, Responsible Care® and Energy Management.

We also conduct 360 assessments to help associates assess their individual development and progression based on feedback from key stakeholders. Participants engage in a 360 assessment feedback process and are assigned an executive mentor, which are used to identify opportunities to develop key aspects of their leadership and share their personal leadership journey with executives. International standards cover areas of Quality, Environmental, Health and Safety, Automotive, Medical Device, Responsible Care® and Energy Management.

This includes masks, protective garments, medical tubing and packaging for personal care products. We also conduct 360 assessments to help associates assess their individual development and progression based on feedback from key stakeholders. These international standards cover areas of Quality, Environmental, Health and Safety, Automotive, Medical Device, Responsible Care and Energy Management.

MEDICAL, FOOD AND TOY REGULATIONS Omnicolor colorants have limited EU food contact compliance, and are not suitable for FDA primary pharmaceutical packaging, cosmetic or medical applications.

Morgan • New Senior Secured Term Loan B and new Senior Unsecured Notes • Potential proceeds from sale of Distribution business modeled to pay off 5.25% senior notes due 2023 and Term Loan • Acquisition aligned with Avient’s track record of disciplined capital allocation policy • Existing dividend policy maintained, focus on deleveraging in the near term (1) Pro forma for the acquisition of Dyneema® and potential divestiture of Distribution, including repayment of senior notes due 2023 and Term Loan Cash and Cash Equivalents 595$ Senior Secured Term Loan due 2026 605$ New Senior Secured Term Loan B 500 Total Senior Secured Debt 1,105$ Senior Unsecured Notes due 2025 650$ New Senior Unsecured Notes 740 Total Senior Unsecured Debt 1,390$ Total Debt 2,495$ Net Debt 1,900$ 2022 Pro forma Adjusted EBITDA 660$ Net Debt / Adjusted EBITDA 2.9x Pro Forma Capitalization (2022 estimates, all figures in $M) TWO-YEAR LEVERAGE GOAL 33 3.5x 2.7x 1.7x 2.9x 2.5x 2.2x 2019PF 2020PF 2022E 2022PF 2023E 2024E Dyneema® AcquisitionClariant Color Acquisition (1) Pro forma for the acquisition of the Clariant Color business (2) Pro forma for the acquisition of Dyneema® and potential divestiture of Distribution, including repayment of senior notes due 2023 and Term Loan (1) (1) (2) 34 PRO FORMA MODELING 2022E Pro Forma Pro Forma ($M) w/ Dyneema w/Sale Revenue 5,100$ 415$ 5,515$ (1,775)$ 3,740$ Adjusted EBITDA 635 130 765 (105) 660 EBITDA % 12% 31% 14% 6% 18% Pro Forma EPS (Adjusted) 3.50$ 0.00$ 3.50$ (0.56)$ 2.94$ Pro Forma EPS (excl. amortization) 3.96$ 0.35$ 4.31$ (0.56)$ 3.75$ Leverage (12/31/2022E) Net Debt / Adjusted EBITDA 1.7x 3.5x 2.9x Avient Dyneema Distribution® ® OUR SPECIALTY JOURNEY ACQUISITION HISTORY 36 Commercial Resources(1) Operating Margins 259 360 $40 $122 Established Acquisitions (> 7 years) + 39% + 210% + 1200 bps (1) Commercial Resources include associate headcount in R&D / Technical, Marketing and Sales CLARIANT COLOR ACQUISITION 37 $133 $205 2019PF 2021 37 Clariant Color EBITDA Growth Purchase Price Multiple 10.8x 7.0x 6.1x 2019PF 2021 2021 w/ Full Synergies • Acquisition of Clariant Color business significantly expanded presence in healthcare, packaging and consumer end markets • Strength of portfolio – double-digit annual EBITDA growth since acquisition • $54 million of synergies realized in 2021 • Acquisition completed on July 1, 2020 for $1.45 billion.

Operating Income $3,783 $4,100 (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition Previous Guidance Current Guidance $3,783 $4,300 $308 $360 $308 $410 $1.93 $2.40 $1.93 $2.80 (1) (1)(1) (1)(1) (1) $442 $457 $560 $1.74 $1.93 $2.80 FULL YEAR 2019 – 2021 ORGANIC GROWTH 23 Sales Adjusted EBITDA $3,981 $3,783 $4,300 + 8% (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition (1)(1) + 27% + 61% 24 BALANCE SHEET • Deleveraging to 1.9x net debt to adjusted EBITDA by the end of 2021 • Driven by record adjusted EBITDA performance and strong free cash flow generation from asset light business • Future cash deployment: M&A, opportunistic share repurchases and balance sheet / continued leverage reduction 3.5x 2.7x 1.9x Net Debt / Adjusted EBITDA ($ in millions) 2021E Adjusted EBITDA 560$ Free Cash Flow 275$ Total Debt 1,860 Less: Cash (800) Net Debt 1,060$ 2021E Net Debt / Adjusted EBITDA 1.9x (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition PEER COMPARISONS 25 As a specialty formulator, we don’t require significant capital investment, as compared to the base resin raw material suppliers we purchase from.

International standards cover areas of Quality, Environmental, Health and Safety, Automotive, Medical Device, Responsible Care® and Energy Management.

Operating Income $3,783 $4,100 (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition Previous Guidance Current Guidance $3,783 $4,300 $308 $360 $308 $410 $1.93 $2.40 $1.93 $2.80 (1) (1)(1) (1)(1) (1) $442 $457 $560 $1.74 $1.93 $2.80 FULL YEAR 2019 – 2021 ORGANIC GROWTH 23 Sales Adjusted EBITDA $3,981 $3,783 $4,300 + 8% (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition (1)(1) + 27% + 61% 24 BALANCE SHEET • Deleveraging to 1.9x net debt to adjusted EBITDA by the end of 2021 • Driven by record adjusted EBITDA performance and strong free cash flow generation from asset light business • Future cash deployment: M&A, opportunistic share repurchases and balance sheet / continued leverage reduction 3.5x 2.7x 1.9x Net Debt / Adjusted EBITDA ($ in millions) 2021E Adjusted EBITDA 560$ Free Cash Flow 275$ Total Debt 1,860 Less: Cash (800) Net Debt 1,060$ 2021E Net Debt / Adjusted EBITDA 1.9x (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition PEER COMPARISONS 25 As a specialty formulator, we don’t require significant capital investment, as compared to the base resin raw material suppliers we purchase from.

USP specifications cover blood and body fluid compatibility/contact applications.

USP specifications cover blood and body fluid compatibility/contact applications.